Online inquiry

IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8930MR)

This product GTTS-WQ8930MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8930MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13979MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ1702MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ11004MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ1164MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ10811MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ13630MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ9638MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ12819MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMS721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW